Active Ingredient: Body Protective Compound 

Other Ingredients: Other Ingredients: Rice Powder, Microcrystalline Cellulose, Vegetable Capsule (Hypromellose)

 BENEFITS

• joint and soft tissue support
• promotes digestive function
• neurological support
• endothelial nitric oxide production

FOR THOSE NEEDING

• Digestive Support; Both Upper & Lower
• Musculoskeletal Support
• Gut Brain Axis Protocols
• Immune System Support

OVERVIEW

BPC-157 is predominately indicated for people who need joint and/or digestive (upper/lower) support. 

There are two dosages available: a 250 mcg dose, ideal for people needing maintenance; and a 500 mcg dose, a higher potency that can be leveraged as a loading dose or applied to cases where more support is needed. 

There are two time-release formula options: rapid and delayed. The rapid release formula is typically for upper GI application. Regarding joint health, rapid release is more appropriate for acute needs, while the delayed release works for more ongoing support. The delayed release formula is intended to reach the lower intestines without succumbing to the harsh environment of the upper digestive system.

DOSAGE FOR DOGS

The current recommendation is to go by the dosage protocol for an average sized human, to calculate the amount per pound, and then apply the same mcg/lb dosage to your dog.

Typical suggested dose for a 150 lb person is 250-500 mcg of BPC-157 orally each day (1.67- 3.33 mcg per lb body weight), so a 60 lb dog could take 100-200 mcg/day of BPC-157.

Multiply your dog’s body weight x 1.67 (low dose) or 3.33 (higher dose) to get your dog’s dose. Ideally, give this amount in divided doses, 2x/day.

Current research in dogs and rats showed that BPC-157 is nontoxic at even high doses.

Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds

Panel Chuanyang Xu ^a 1, Lijuan Sun ^b 1, FengLing Ren ^c, Ping Huang ^d, Zhuang Tian ^d, Jiazhen Cui ^d, Wangqian Zhang ^a, Shuning Wang ^a, Kuo Zhang ^a, Lei He ^a, Wei Zhang ^a, Cun Zhang ^a, Qiang Hao ^a, Yingqi Zhang ^a, Meng Li ^a, Weina Li ^a

Show more https://doi.org/10.1016/j.yrtph.2020.104665

Highlights

• BPC157 did not show any test-related effects in the single-dose toxicity study.
• BPC157 was well tolerated in repeated-dose toxicity evaluations.
• BPC157 caused mild local irritation and showed good tolerance.
• BPC157 showed no genetic or embryo-fetal toxicity.

Abstract

BPC157 displays protective activity in various organs and tissues. This report presents preclinical toxicity studies with BPC157 in mice, rats, rabbits and dogs. The single-dose toxicity study did not show any test-related effects that could be attributed to the test article. In repeated-dose toxicity evaluations, BPC157 was well tolerated in dogs, with no abnormal changes between the BPC157-treated groups and the solvent control group, with the exception of a decrease in creatinine level at a dose of 2 mg/kg but not at lower doses. The animals recovered spontaneously after 2 weeks of withdrawal. This may be due to the pharmacological activity of BPC157. A local tolerance test showed that the irritation caused by BPC157 was mild. BPC157 also showed no genetic or embryo-fetal toxicity. In summary, BPC157 was well tolerated and did not cause any serious toxicity in mice, rats, rabbits and dogs. These preclinical safety data contribute to the initiation of an ongoing clinical study. Based on the stability and protective effect of BPC157, which has been widely reported, BPC157 may have a better application prospect than the widely used cytokine drugs in wound therapy.